Carmen G. Rea

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

Francesca Ligorio, Giovanni Fucà, Emma Zattarin et al. · Cancers · 2021 · 107 citations · Full text

Medicine, Immunology, Oncology +17

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study

Giuseppe Buono, Anna Crispo, Mario Giuliano et al. · Breast Cancer Research and Treatment · 2020 · 70 citations · Full text

Medicine, Endocrinology, Oncology +10

Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients?

Lorenzo Dottorini, Fausto Petrelli, Antonio Ghidini et al. · Journal of Clinical Oncology · 2023 · 13 citations

Medicine, Geriatric Medicine, Oncology +14

337P Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study

Federico Nichetti, Antonio Marra, Carlo Alberto Giorgi et al. · Annals of Oncology · 2020 · 11 citations

Medicine, Oncology, Pharmacology +17

Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET)

Claudio Vernieri, Federico Nichetti, Luca Lalli et al. · Clinical Cancer Research · 2021 · 10 citations · Full text

Medicine, Oncology, Pharmacology +17